Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The Chinese company is branching out from its core genomics business to liquid biopsy cancer screening and monitoring as it eyes areas for global expansion.
The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.
In PNAS this week: rearrangements found in acute myeloid leukemia, DNA double-strand break repair patterns in model of hepatocellular carcinoma, and more.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
